Current Good Manufacturing Practice for Finished Pharmaceuticals
The foundational cGMP regulation governing finished pharmaceutical manufacturing in the US market. Establishes minimum quality standards for organization, buildings, equipment, production, packaging, and records.
What this does not cover
stated in the document's own scope- Covers finished pharmaceuticals; the GMP for active pharmaceutical ingredients is addressed by ICH Q7, adopted by FDA as guidance rather than codified in Part 211.
- Governs manufacturing quality, not product approval — whether a drug may be marketed is decided through the NDA/ANDA/BLA review pathway, not Part 211.
- Applies to drugs; medical devices are governed by the separate Quality System Regulation at 21 CFR Part 820, and biological products add the requirements of 21 CFR Parts 600–680.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
21 CFR Part 211 is the current Good Manufacturing Practice regulation for finished pharmaceuticals in the United States — the operational core of US drug GMP. It sets the minimum requirements a manufacturer must meet across the whole production system: organisation and personnel, buildings and facilities, equipment, control of components and closures, production and process controls, packaging and labelling, holding and distribution, laboratory controls, records and reports, and returned or salvaged product. It applies to human and veterinary drugs, whether the maker is the applicant or a contractor, and it is the standard against which a finished drug is judged to have been made under adequate controls.
Scope & applicability
Applies to all manufacturers, processors, packagers, and holders of finished pharmaceuticals intended for human use and distributed in the United States.
Legal basis & how it acquires force
Part 211 is a binding regulation in Title 21 of the Code of Federal Regulations, issued under sections 501, 502, and 505 of the Federal Food, Drug, and Cosmetic Act together with the Public Health Service Act. Its statutory hook is FD&C Act §501(a)(2)(B): a drug is deemed adulterated if it was not manufactured in conformity with current good manufacturing practice. Part 211 is FDA’s codification of what that phrase requires for finished pharmaceuticals, so conformance is a legal obligation, not guidance.
Document structure
| Part | Covers |
|---|---|
| Subparts A–B | General provisions and scope; organisation and personnel, including the responsibilities of the quality control unit |
| Subparts C–D | Buildings and facilities; equipment design, cleaning, and maintenance |
| Subpart E | Control of components, drug product containers, and closures — receipt, testing, and approval before use |
| Subparts F–G | Production and process controls; packaging and labelling control, including expiration dating |
| Subparts H–I | Holding and distribution; laboratory controls, stability testing, and specifications |
| Subparts J–K | Records and reports, including batch production and control records; returned and salvaged drug products |
Key requirements
- Written procedures required for all GMP operations with second-person verification
- Equipment qualification and calibration records maintained and current
- Production and process controls validated with documented protocols and reports
- Out-of-specification (OOS) investigations must be thorough with root cause identified
- Batch records reviewed and approved before product release
- Laboratory controls including method validation and instrument qualification
- Complaint handling and annual product review programmes
Implementation tips
- Map every SOP to the specific CFR subpart it addresses — auditors work section by section
- Establish a deviation trending programme; FDA expects pattern recognition, not just closure
- Annual Product Review (§211.180) is a common audit starting point — keep it current and analytical
- Electronic records under §211.68 must demonstrate ALCOA+ attributes — document your data governance policy
Revision notes
April 2023 update clarified electronic data integrity expectations in line with FDA data integrity guidance. No structural changes to core GMP requirements.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
Part 211 is the US analogue of EU GMP (Directive 2003/94/EC and the EudraLex Volume 4 chapters) and of the PIC/S GMP Guide, and it interlocks with the ICH quality guidelines — ICH Q7 for active ingredients, Q9 for risk management, and Q10 for the pharmaceutical quality system. The United States is not a PIC/S member state, but FDA participates in the scheme’s activities and the substantive expectations converge, which is why the same quality-system concepts recur across regions.
21 CFR Part 211: frequently asked questions
Quick answers to common questions about 21 CFR Part 211.
What statute makes 21 CFR Part 211 enforceable?
The Federal Food, Drug, and Cosmetic Act. Section 501(a)(2)(B) deems a drug adulterated if it was not made in conformity with current good manufacturing practice, and Part 211 is FDA’s codified statement of what cGMP requires for finished pharmaceuticals.
Does Part 211 cover active pharmaceutical ingredients?
No. Part 211 covers finished drug products. GMP for active ingredients is set out in ICH Q7, which FDA recognises as guidance representing current good manufacturing practice for APIs.
How does Part 211 relate to Part 210?
Part 210 states the status, scope, and definitions for the cGMP regulations generally; Part 211 contains the substantive requirements for finished pharmaceuticals. They are read together as one framework.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.